Editorial: histologic normalisation in ulcerative colitis. Authors’ reply by Cushing, Kelly C. & Ananthakrishnan, Ashwin N.
     |  401INVITED EDITORIALS
© 2020 John Wiley & Sons Ltd
with ulcerative colitis in complete endoscopic remission. Aliment 
Pharmacol Ther. 2020;51:346-354.
 6. Christensen B, Hanauer SB, Erlich J, et al. Histologic normalization 
occurs in ulcerative colitis and is associated with improved clinical 
outcomes. Clin Gastroenterol Hepatol. 2017;15:1557-1564.
 7. Lemmens B, Arijs I, Van Assche G, et al. Correlation between the en-
doscopic and histologic score in assessing the activity of ulcerative 
colitis. Inflamm Bowel Dis. 2013;19:1194-1201.
DOI: 10.1111/apt.15621  
Editorial: histologic normalisation in ulcerative colitis. Authors' 
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We thank Drs Pai, Jairath and Feagan for their insights regarding our 
work and for the robust discussion on the role of histologic activity in 
ulcerative colitis.1,2 There is mounting evidence demonstrating persis-
tent histologic activity to be associated with a worse disease course 
including risk of relapses, hospitalisation, surgery and colorectal neo-
plasia.3-5 However, there are mostly retrospective and few rigorous 
studies examining the utility of histologic remission as a therapy tar-
get once the two more commonly recommended endpoints—clinical 
remission and endoscopic remission—have been achieved.6 In distinc-
tion from our study, most of the prior studies on histologic remission 
also included patients with endoscopically active disease or those 
with mild persistent inflammation (Mayo 1). Given the correlation be-
tween endoscopic severity and histology, and the recognition that 
those with Mayo 1 endoscopic activity may have worse outcomes 
than those with Mayo 0,7 such studies may be biased towards show-
ing a higher predictive value of neutrophilic infiltration. As pointed 
out by Drs Pai et al, the likelihood of histologic normalisation (scored 
blinded in our study) is much greater in our cohort that was restricted 
to those with complete endoscopic remission (Mayo 0). While we ac-
knowledge their concerns about sample size, ours remains one of the 
largest to examine the value of blinded scoring of histologic activ-
ity in those with complete endoscopic remission. As the field moves 
towards assessing both the clinical utility and cost-effectiveness of 
histologic healing, trials, such as proposed by Pai et al, examining the 
incremental value of histology in those who have already achieved 
endoscopic and clinical remission are essential to establish the rel-
evant features that lead to improved outcomes for all our patients.
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